Referanser

Aabedi, A. A., Young, J. S., Zhang, Y., Ammanuel, S., Morshed, R. A., Dalle Ore, C., Brown, D., Phillips, J. J., ... Hervey-Jumper, S. L. (2022). Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery, 90(1), 124-130.

Aaronson, N. K., Taphoorn, M. J., Heimans, J. J., Postma, T. J., Gundy, C. M., Beute, G. N., Slotman, B. J., & Klein, M. (2011). Compromised health-related quality of life in patients with low-grade glioma. Journal of Clinical Oncology, 29(33), 4430-5.

Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougere, C., Pope, W., ... Tonn, J. C. (2016). Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology, 18(9), 1199-208.

Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., ... van den Bent, M. (2013). Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology, 31(26), 3212-8.

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1521-1532.

Belhawi, S. M., Hoefnagels, F. W., Baaijen, J. C., Aliaga, E. S., Reijneveld, J. C., Heimans, J. J., Barkhof, F., Vandertop, W. P., & Hamer, P. C. (2011). Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. European Radiology, 21(7), 1526-34.

Bell, E. H., Zhang, P., Shaw, E. G., Buckner, J. C., Barger, G. R., Bullard, D. E., Mehta, M. P., Gilbert, M. R., ... Chakravarti, A. (2020). Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology, 38(29), 3407-3417.

Berghoff, A., & van den Bent, M. (2019). How I treat anaplastic glioma without 1p/19q codeletion. ESMO Open, 4(Suppl 2), e000534.

Bleehen, N. M., & Stenning, S. P. (1991). A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. British Journal of Cancer, 64(4), 769-74.

Blonski, M., Pallud, J., Goze, C., Mandonnet, E., Rigau, V., Bauchet, L., Fabbro, M., Beauchesne, P., ... Taillandier, L. (2013). Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients. Journal of Neuro-Oncology, 113(2), 267-75.

Blumenthal, D. T., Gorlia, T., Gilbert, M. R., Kim, M. M., Burt Nabors, L., Mason, W. P., Hegi, M. E., Zhang, P., ... Stupp, R. (2017). Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-Oncology, 19(8), 1119-1126.

Blumenthal, D. T., Won, M., Mehta, M. P., Curran, W. J., Souhami, L., Michalski, J. M., Rogers, C. L., & Corn, B. W. (2009). Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. Journal of Clinical Oncology, 27(5), 733-9.

Brandal, P., Marienhagen, K., Nyström, P. W., Danielsen, T. (2023). Toleransedoser til risikoorganer ved strålebehandling av sentralnervesystemet (CNS) (Teknisk dokument nr. 29). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/inline/a5d17cc9-d8fa-4138-8ffc-c091eb2d122e:db1b583d5d4b878b3311ab387f73b96ab89ccc3a/Teknisk%20dokument%2029%20Toleransedoser%20og%20anbefalte%20dosegrenser%20til%20risikoorganer%20ved%20str%C3%A5lebehandling%20av%20sentralnervesystemet%20.pdf

Brandsma, D., & van den Bent, M. J. (2009). Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology, 22(6), 633-8.

Brown, T. J., Brennan, M. C., Li, M., Church, E. W., Brandmeir, N. J., Rakszawski, K. L., Patel, A. S., Rizk, E. B., ... Glantz, M. (2016). Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA oncology, 2(11), 1460-1469.

Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., ... Curran, W. J. ,. J. (2016). Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. New England Journal of Medicine, 374(14), 1344-55.

Buglione, M., Pedretti, S., Poliani, P. L., Liserre, R., Gipponi, S., Spena, G., Borghetti, P., Pegurri, L., ... Magrini, S. M. (2016). Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. Journal of Neuro-Oncology, 128(2), 303-12.

Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., ... Curran, W. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 24(18), 2707-14.

Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., ... Mehta, M. (2013). Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology, 31(3), 337-43.

Cao, J. Q., Fisher, B. J., Bauman, G. S., Megyesi, J. F., Watling, C. J., & Macdonald, D. R. (2012). Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. Journal of Neuro-Oncology, 107(2), 395-405.

Capelle, L., Fontaine, D., Mandonnet, E., Taillandier, L., Golmard, J. L., Bauchet, L., Pallud, J., Peruzzi, P., ... Duffau, H. (2013). Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of Neurosurgery, 118(6), 1157-68.

Chaichana, K. L., Jusue-Torres, I., Navarro-Ramirez, R., Raza, S. M., Pascual-Gallego, M., Ibrahim, A., Hernandez-Hermann, M., Gomez, L., ... Quinones-Hinojosa, A. (2014). Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncology, 16(1), 113-22.

Chaichana, K. L., McGirt, M. J., Laterra, J., Olivi, A., & Quinones-Hinojosa, A. (2010). Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. Journal of Neurosurgery, 112(1), 10-7.

Chang, E. F., Potts, M. B., Keles, G. E., Lamborn, K. R., Chang, S. M., Barbaro, N. M., & Berger, M. S. (2008). Seizure characteristics and control following resection in 332 patients with low-grade gliomas. Journal of Neurosurgery, 108(2), 227-35.

Chang, E. L., Akyurek, S., Avalos, T., Rebueno, N., Spicer, C., Garcia, J., Famiglietti, R., Allen, P. K., ... Maor, M. H. (2007). Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 68(1), 144-50.

Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., ... Cloughesy, T. (2014). Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 709-22.

Claus, E. B., Horlacher, A., Hsu, L., Schwartz, R. B., Dello-Iacono, D., Talos, F., Jolesz, F. A., & Black, P. M. (2005). Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer, 103(6), 1227-33.

Climans, S. A., Grunfeld, E., Mason, W. P., & Chan, K. K. W. (2022). Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. Neuro-Oncology, 24(10), 1738-1748.

Climans, S. A., Mason, W. P., Grunfeld, E., & Chan, K. (2022). Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. Journal of Neuro-Oncology, 159(3), 665-674.

Combs, S. E., Thilmann, C., Edler, L., Debus, J., & Schulz-Ertner, D. (2005). Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. Journal of Clinical Oncology, 23(34), 8863-9.

Darlix, A., Baumann, C., Lorgis, V., Ghiringhelli, F., Blonski, M., Chauffert, B., Zouaoui, S., Pinelli, C., ... Taillandier, L. (2013). Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Research, 33(8), 3467-74.

Douw, L., Klein, M., Fagel, S. S., van den Heuvel, J., Taphoorn, M. J., Aaronson, N. K., Postma, T. J., Vandertop, W. P., ... Heimans, J. J. (2009). Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurology, 8(9), 810-8.

Doz, F., van Tilburg, C. M., Geoerger, B., Hojgaard, M., Ora, I., Boni, V., Capra, M., Chisholm, J., ... Perreault, S. (2022). Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro-Oncology, 24(6), 997-1007.

Dropcho, E. J., & Soong, S. J. (1996). The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology, 47(3), 684-90..

Fogh, S. E., Andrews, D. W., Glass, J., Curran, W., Glass, C., Champ, C., Evans, J. J., Hyslop, T., ... Werner-Wasik, M. (2010). Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. Journal of Clinical Oncology, 28(18), 3048-53.

Galldiks, N., Law, I., Pope, W. B., Arbizu, J., & Langen, K. J. (2017). The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. NeuroImage. Clinical, 13, 386-394.

Galldiks, N., Niyazi, M., Grosu, A. L., Kocher, M., Langen, K. J., Law, I., Minniti, G., Kim, M. M., ... Tonn, J. C. (2021). Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro-Oncology, 23(6), 881-893.

Gebhardt, B. J., Dobelbower, M. C., Ennis, W. H., Bag, A. K., Markert, J. M., & Fiveash, J. B. (2014). Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiation Oncology (London, England), 9, 130.

Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A., Klein, M., Postma, T. J., van den Bent, M. J., Beute, G. N., ... Aaronson, N. K. (2009). Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology, 27(22), 3712-22.

Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., ... Mehta, M. P. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699-708.

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., ... Mehta, M. P. (2013). Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology, 31(32), 4085-91.

Gramatzki, D., Kickingereder, P., Hentschel, B., Felsberg, J., Herrlinger, U., Schackert, G., Tonn, J. C., Westphal, M., ... Weller, M. (2017). Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 88(15), 1422-1430.

Grogan, P. T., Deming, D. A., Helgager, J., Ruszkiewicz, T., Baskaya, M. K., Howard, S. P., & Robins, H. I. (2022). Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma. Neuro-oncology advances, 4(1), vdac046.

Habets, E. J., Taphoorn, M. J., Nederend, S., Klein, M., Delgadillo, D., Hoang-Xuan, K., Bottomley, A., Allgeier, A., ... Reijneveld, J. C. (2014). Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of Neuro-Oncology, 116(1), 161-8.

Halasz, L. M., Attia, A., Bradfield, L., Brat, D. J., Kirkpatrick, J. P., Laack, N. N., Lalani, N., Lebow, E. S., ... Shih, H. A. (2022). Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 12(5), 370-386.

Hanna, C., Lawrie, T. A., Rogozinska, E., Kernohan, A., Jefferies, S., Bulbeck, H., Ali, U. M., Robinson, T., & Grant, R. (2020). Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database of Systematic Reviews, 3(3), CD013261.

Hart, M. G., Garside, R., Rogers, G., Stein, K., & Grant, R. (2013). Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews, (4), CD007415.

Helse- og omsorgsdepartementet (2006). Nasjonal strategi for kreftområdet 2006-2009 Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/

Helse- og omsorgsdepartementet (2006). Nasjonal helseplan (2007–2010) (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf

Helse- og omsorgsdepartementet (2013). Sammen - mot kreft: nasjonal kreftstrategi 2013-2017 Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/sammen---mot-kreft/id728818/

Helse- og omsorgsdepartementet (2018). Leve med kreft: nasjonal kreftstrategi (2018–2022) Oslo: Helse- og omsorgsdepartementet. Hentet fra https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/

Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R. D., ... Glas, M. (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet, 393(10172), 678-688.

Hervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., ... Molinaro, A. M. (2023). Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. Journal of Clinical Oncology, , JCO2102929.

Jaeckle, K. A., Ballman, K. V., van den Bent, M., Giannini, C., Galanis, E., Brown, P. D., Jenkins, R. B., Cairncross, J. G., ... Vogelbaum, M. A. (2021). CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 23(3), 457-467.

Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgard, G., & Solheim, O. (2012). Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 308(18), 1881-8.

Jakola, A. S., Pedersen, L. K., Skjulsvik, A. J., Myrmel, K., Sjavik, K., & Solheim, O. (2022). The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. Journal of Neurosurgery, , 1-8.

Jakola, A. S., Skjulsvik, A. J., Myrmel, K. S., Sjavik, K., Unsgard, G., Torp, S. H., Aaberg, K., Berg, T., ... Solheim, O. (2017). Surgical resection versus watchful waiting in low-grade gliomas. Annals of Oncology, 28(8), 1942-1948.

Jakola, A. S., Unsgard, G., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., & Solheim, O. (2012). Low grade gliomas in eloquent locations - implications for surgical strategy, survival and long term quality of life. PloS One, 7(12), e51450.

Jakola, A. S., Unsgard, G., Myrmel, K. S., Kloster, R., Torp, S. H., Sagberg, L. M., Lindal, S., & Solheim, O. (2014). Surgical strategies in low-grade gliomas and implications for long-term quality of life. Journal of Clinical Neuroscience, 21(8), 1304-9.

Jansen, E. P., Dewit, L. G., van Herk, M., & Bartelink, H. (2000). Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiotherapy and Oncology, 56(2), 151-6.

Karim, A. B., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H., Thomas, D. G., Mascarenhas, F., Horiot, J. C., ... van Glabbeke, M. (1996). A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International Journal of Radiation Oncology, Biology, Physics, 36(3), 549-56.

Kavouridis, V. K., Boaro, A., Dorr, J., Cho, E. Y., Iorgulescu, J. B., Reardon, D. A., Arnaout, O., & Smith, T. R. (2019). Contemporary assessment of extent of resection in molecularly defined categories of diffuse low-grade glioma: a volumetric analysis. Journal of Neurosurgery, , 1-11.

Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J. S., Jadaud, E., ... Delattre, J. Y. (2007). Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine, 356(15), 1527-35.

Kesari, S., Schiff, D., Drappatz, J., LaFrankie, D., Doherty, L., Macklin, E. A., Muzikansky, A., Santagata, S., ... Wen, P. Y. (2009). Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clinical Cancer Research, 15(1), 330-7.

Kiebert, G. M., Curran, D., Aaronson, N. K., Bolla, M., Menten, J., Rutten, E. H., Nordman, E., Silvestre, M. E., ... Karim, A. B. (1998). Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. European Journal of Cancer, 34(12), 1902-9.

Kruser, T. J., Mehta, M. P., & Robins, H. I. (2013). Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 13(4), 389-403.

Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., ... Sawaya, R. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery, 95(2), 190-8.

Laigle-Donadey, F., Metellus, P., Guyotat, J., Menei, P., Proust, F., Dufour, H., Chinot, O., Honnorat, J., ... Anocef, I. (2022). Surgery for glioblastomas in the elderly: an Association des Neuro-oncologues d'Expression Francaise (ANOCEF) trial. Journal of Neurosurgery, , 1-7.

Landberg, T., Chavaudra, J., Dobbs, J., Gerard, J. P., Hanks, G., Horiot, J. C., Johansson, K. A., Möller, T., ... Svensson, H. (1999). Report 62: prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU report 50). Journal of the International Commission on Radiation Units and Measurements, os32(1)

Landberg, T., Chavaudra, J., Dobbs, J., Hanks, G., Johansson, K., Möller, T., & Purdy, J. (1993). Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Journal of the International Commission on Radiation Units and Measurements, os26(1)

Laperriere, N., Zuraw, L., & Cairncross, G. (2002). Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiotherapy and Oncology, 64(3), 259-73.

Lassman, A. B., Hoang-Xuan, K., Polley, M. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., ... van den Bent, M. J. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 40(23), 2539-2545.

Law, I., Albert, N. L., Arbizu, J., Boellaard, R., Drzezga, A., Galldiks, N., la Fougere, C., Langen, K. J., ... Weller, M. (2019). Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 46(3), 540-557.

Lawrence, Y. R., Blumenthal, D. T., Matceyevsky, D., Kanner, A. A., Bokstein, F., & Corn, B. W. (2011). Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?. Journal of Neuro-Oncology, 105(1), 1-7.

Leighton, C., Fisher, B., Macdonald, D., Stitt, L., Bauman, G., & Cairncross, J. (2007). The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. Journal of Neuro-Oncology, 82(2), 165-70.

Levernes, S. (2012). Volum og doser i ekstern stråleterapi: definisjoner og anbefalinger (StrålevernRapport 2012:9). Østerås: Statens strålevern. Hentet fra https://dsa.no/medisinsk-stralebruk/kvist/_/attachment/download/bee8860b-36d1-42e7-8d64-f5ad4fcef2e8:8ebb86decddc2818ec31e4999d26cdf7aec14ac2/StralevernRapport_09-2012.pdf

Levernes, S. (2019). Faglige anbefalinger for nomenklatur for volumer i stråleterapi (Teknisk dokument 14). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/download/9d2a42a5-241e-4299-86cf-6b02a0abf3b9:2400dff7cb71f4bff583473d690fcb79650dd59e/TekniskDokument14_rev2020.pdf

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., ... Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA oncology, 9(1), 112-121.

Lim, M., Weller, M., Idbaih, A., Steinbach, J., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J., ... Omuro, A. (2022). Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology, 24(11), 1935-1949.

Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., ... Ellison, D. W. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 23(8), 1231-1251.

Majewska, P., Sagberg, L. M., Reinertsen, I., Gulati, S., Jakola, A. S., & Solheim, O. (2021). What is the current clinico-radiological diagnostic accuracy for intracranial tumours?. Acta Neurologica Scandinavica, 144(2), 142-148.

Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., ... Nordic Clinical Brain Tumour Study, G. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, 13(9), 916-26.

Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., ... Capelle, L. (2003). Continuous growth of mean tumor diameter in a subset of grade II gliomas. Annals of Neurology, 53(4), 524-528.

Marienhagen, K., Djupvik, L. H., Danielsen, T. (2020). Faglige anbefalinger for inntegning av risikoorganer i CNS (Teknisk dokument 16). Østerås: Direktoratet for strålevern og atomsikkerhet. Hentet fra https://dsa.no/publikasjoner/_/attachment/download/401a60b3-b7db-4c4a-b741-da0a70c43b20:f0c3325a0ec4a43b2335cf17df266e4e7c34408c/Teknisk%20dokument16_rev.pdf

Mayer, R., & Sminia, P. (2008). Reirradiation tolerance of the human brain. International Journal of Radiation Oncology, Biology, Physics, 70(5), 1350-60.

McGirt, M. J., Chaichana, K. L., Attenello, F. J., Weingart, J. D., Than, K., Burger, P. C., Olivi, A., Brem, H., & Quinones-Hinojosa, A. (2008). Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery, 63(4), 700-7; author reply 707-8.

Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., ... Cloughesy, T. F. (2023). Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. New England Journal of Medicine, Jun 4, Epub ahead of print.

Minniti, G., Scaringi, C., Baldoni, A., Lanzetta, G., De Sanctis, V., Esposito, V., & Enrici, R. M. (2013). Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. International Journal of Radiation Oncology, Biology, Physics, 86(2), 285-91.

Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., ... Berger, M. S. (2020). Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA oncology, 6(4), 495-503.

Munkvold, B. K. R., Solheim, O., Bartek, J. ,. J., Corell, A., de Dios, E., Gulati, S., Helseth, E., Holmgren, K., ... Jakola, A. S. (2021). Variations in the management of diffuse low-grade gliomas-A Scandinavian multicenter study. Neuro-oncology practice, 8(6), 706-717.

Nelson, D. F., Diener-West, M., Horton, J., Chang, C. H., Schoenfeld, D., & Nelson, J. S. (1988). Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monographs, (6), 279-84.

Niyazi, M., Andratschke, N., Bendszus, M., Chalmers, A. J., Erridge, S. C., Galldiks, N., Lagerwaard, F. J., Navarria, P., ... Minniti, G. (2023). ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiotherapy and Oncology, 184, 109663.

Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S. C., Fiorentino, A., Grosu, A. L., Lagerwaard, F. J., ... Belka, C. (2016). ESTRO-ACROP guideline "target delineation of glioblastomas". Radiotherapy and Oncology, 118(1), 35-42.

Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., ... Weller, M. (2023). Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro-Oncology, 25(1), 123-134.

Osborn, A. G., Louis, D. N., Poussaint, T. Y., Linscott, L. L., & Salzman, K. L. (2022). The 2021 World Health Organization Classification of Tumors of the Central Nervous System: What Neuroradiologists Need to Know. AJNR: American Journal of Neuroradiology, 43(7), 928-937.

Pace, A., Vidiri, A., Galie, E., Carosi, M., Telera, S., Cianciulli, A. M., Canalini, P., Giannarelli, D., ... Carapella, C. M. (2003). Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Annals of Oncology, 14(12), 1722-6.

Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., ... Capelle, L. (2013). Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro-Oncology, 15(5), 595-606.

Perry, J. R., Laperriere, N., O'Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., ... Mason, W. P. (2017). Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine, 376(11), 1027-1037.

Phillips, C., Guiney, M., Smith, J., Hughes, P., Narayan, K., & Quong, G. (2003). A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiotherapy and Oncology, 68(1), 23-6.

Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Afra, D., Cornu, P., ... Karim, A. B. (2002). Prognostic factors for survival in adult patients with cerebral low-grade glioma. Journal of Clinical Oncology, 20(8), 2076-84.

Preusser, M., & van den Bent, M. J. (2022). Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?. Neuro-Oncology,

Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., ... Friedman, H. S. (2003). Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology, 21(4), 646-51.

Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., ... Weller, M. (2020). Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA oncology, 6(7), 1003-1010.

Rees, J., Watt, H., Jager, H. R., Benton, C., Tozer, D., Tofts, P., & Waldman, A. (2009). Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. European Journal of Radiology, 72(1), 54-64.

Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. (2007). Journal of the International Commission on Radiation Units and Measurements, 7(7)

Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT). (2010). Journal of the International Commission on Radiation Units and Measurements, 10(1)

Roa, W., Kepka, L., Kumar, N., Sinaika, V., Matiello, J., Lomidze, D., Hentati, D., Guedes de Castro, D., ... Fidarova, E. (2015). International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 33(35), 4145-50.

Roh, T. H., Kang, S. G., Moon, J. H., Sung, K. S., Park, H. H., Kim, S. H., Kim, E. H., Hong, C. K., ... Chang, J. H. (2019). Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. Journal of Neurosurgery, 132(3), 895-901.

Ryu, S., Buatti, J. M., Morris, A., Kalkanis, S. N., Ryken, T. C., & Olson, J. J. (2014). The role of radiotherapy in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 118(3), 489-99.

Rønning, P. A., Helseth, E., Meling, T. R., & Johannesen, T. B. (2012). A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology, 14(9), 1178-84.

Sanai, N., Polley, M. Y., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011). An extent of resection threshold for newly diagnosed glioblastomas. Journal of Neurosurgery, 115(1), 3-8.

Schei, S., Solheim, O., Jakola, A. S., & Sagberg, L. M. (2020). Perioperative fatigue in patients with diffuse glioma. Journal of Neuro-Oncology, 147(1), 97-107.

Scott, J. N., Brasher, P. M., Sevick, R. J., Rewcastle, N. B., & Forsyth, P. A. (2002). How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology, 59(6), 947-9.

Sharma, R. R., Singh, D. P., Pathak, A., Khandelwal, N., Sehgal, C. M., Kapoor, R., Ghoshal, S., Patel, F. D., & Sharma, S. C. (2003). Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurology India, 51(4), 512-7.

Shaw, E., Arusell, R., Scheithauer, B., O'Fallon, J., O'Neill, B., Dinapoli, R., Nelson, D., Earle, J., ... Abrams, R. (2002). Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 20(9), 2267-76.

Shaw, E. G., Berkey, B., Coons, S. W., Bullard, D., Brachman, D., Buckner, J. C., Stelzer, K. J., Barger, G. R., ... Mehta, M. (2008). Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. Journal of Neurosurgery, 109(5), 835-41.

Shaw, E. G., Wang, M., Coons, S. W., Brachman, D. G., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., ... Mehta, M. P. (2012). Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of Clinical Oncology, 30(25), 3065-70.

Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., Vandenberg, S., ... Berger, M. S. (2008). Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. Journal of Clinical Oncology, 26(8), 1338-45.

Stewart, L. A. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359(9311), 1011-8.

Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., Reulen, H. J., & Group, A. L. S. (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncology, 7(5), 392-401.

Stummer, W., Reulen, H. J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J. C., Rohde, V., Oppel, F., ... Pietsch, T. (2008). Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62(3), 564-76; discussion 564-76.

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y. K., Aldape, K. D., Lhermitte, B., ... Weller, M. (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10), 1100-8.

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., ... Mirimanoff, R. O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5), 459-66.

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., ... Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-96.

Stupp, R., Reni, M., Gatta, G., Mazza, E., & Vecht, C. (2007). Anaplastic astrocytoma in adults. Critical Reviews in Oncology/Hematology, 63(1), 72-80.

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., ... Ram, Z. (2015). Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 314(23), 2535-43.

Suchorska, B., Weller, M., Tabatabai, G., Senft, C., Hau, P., Sabel, M. C., Herrlinger, U., Ketter, R., ... Wirsching, H. G. (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4), 549-56.

Tesileanu, C. M. S., Sanson, M., Wick, W., Brandes, A. A., Clement, P. M., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., ... van den Bent, M. J. (2022). Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 28(12), 2527-2535.

Tsien, C. I., Pugh, S. L., Dicker, A. P., Raizer, J. J., Matuszak, M. M., Lallana, E. C., Huang, J., Algan, O., ... Mehta, M. P. (2023). NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology, 41(6), 1285-1295.

van den Bent, M. J., Afra, D., de Witte, O., Ben Hassel, M., Schraub, S., Hoang-Xuan, K., Malmstrom, P. O., Collette, L., ... Karim, A. B. (2005). Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 366(9490), 985-90.

van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., ... Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103), 1645-1653.

van den Bent, M. J., Brandes, A. A., Taphoorn, M. J., Kros, J. M., Kouwenhoven, M. C., Delattre, J. Y., Bernsen, H. J., Frenay, M., ... Hoang-Xuan, K. (2013). Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology, 31(3), 344-50.

van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J., Bernsen, H. J., Frenay, M., Tijssen, C. C., ... Gorlia, T. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology, 24(18), 2715-22.

van den Bent, M. J., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Wick, W., Clement, P. M., ... Baumert, B. G. (2016). Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. Journal of Clinical Oncology, 34(Suppl 18), LBA2000.

van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., ... Baumert, B. G. (2021). Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncology, 22(6), 813-823.

Wallner, K. E., Galicich, J. H., Krol, G., Arbit, E., & Malkin, M. G. (1989). Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. International Journal of Radiation Oncology, Biology, Physics, 16(6), 1405-9.

Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., ... Sampson, J. H. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncology, 18(10), 1373-1385.

Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9), e370-9.

Weller, M., Stupp, R., Hegi, M. E., van den Bent, M., Tonn, J. C., Sanson, M., Wick, W., & Reifenberger, G. (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14 Suppl 4, iv100-8.

Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F., von Bubnoff, N., van Linde, M. E., ... Subbiah, V. (2022). Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncology, 23(1), 53-64.

Wen, P. Y., Yung, W. K., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., ... Prados, M. D. (2009). Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology, 11(6), 853-60.

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., ... Weller, M. (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7), 707-15.

Wijnenga, M. M. J., French, P. J., Dubbink, H. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Smits, M., Gahrmann, R., ... van den Bent, M. J. (2018). The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology, 20(1), 103-112.